Study: Tecovirimat effective as early treatment for mpox in those with HIV

People with HIV who were treated with tecovirimat within the first 7 days of mpox symptom onset were 13 times less likely to progress to severe mpox disease compared with those not treated or treated late, a recent study found.
According to Bruce Aldred, MD, an assistant professor in the department of medicine at Emory University School of Medicine, and colleagues, the 2022 mpox outbreak disproportionately affected people with HIV (PWH).
“This population may develop more severe mpox disease manifestations and worse clinical outcomes, especially individuals with lower CD4 T-cell counts and

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.